ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0147

Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
Abstract Number: 0148

Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
Abstract Number: 0149

Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Abstract Number: 0150

Mortality in Anca-associated Vasculitis
Abstract Number: 0151

Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
Abstract Number: 0152

Exploring internet use and health information behaviour in patients with inflammatory rheumatic musculoskeletal diseases (RMD)
Abstract Number: 0153

Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Abstract Number: 0154

Incidence and Prevalence of Connective Tissue Diseases with Interstitial Lung Disease (CTD-ILD) in the United States
Abstract Number: 0155

Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
Abstract Number: 0156

Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
Abstract Number: 0157

Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Abstract Number: 0158

Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Abstract Number: 0159

Prenatal and Early-Life Environmental Exposures in Juvenile-Onset Systemic Autoimmune Rheumatic Diseases
Abstract Number: 0161

Risk Factors and Clinical Predictors of Lung Cancer in Systemic Sclerosis: A Matched Case-Control Study from a Michigan Cohort
Abstract Number: 0162

Clinical Relevance of Systematic Comorbidity Screening in Autoimmune and Inflammatory Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].